MBX Biosciences, Inc. Payments to Acquire Marketable Securities
MBX Biosciences, Inc. (MBX) reported Payments to Acquire Marketable Securities of $208.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- MBX Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $53.89M, a 13.62% increase year-over-year.
- MBX Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $154.16M, a 161.76% increase year-over-year.
- MBX Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $205.43M, a 134.77% increase year-over-year.
- MBX Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $46.40M, a 63.68% decline year-over-year.
- MBX Biosciences, Inc. payments to acquire marketable securities for fiscal 2025 was $358.15M, a 49.56% increase from fiscal 2024.
- MBX Biosciences, Inc. payments to acquire marketable securities for fiscal 2024 was $239.47M, a 275.36% increase from fiscal 2023.
- MBX Biosciences, Inc. payments to acquire marketable securities for fiscal 2023 was $63.80M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $208.05M 10-Q · filed 2026-08-06 | $413.48M derived: sum of 3 quarters · filed 2026-08-06 | $459.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $154.16M 10-Q · filed 2026-05-07 | $359.59M derived: sum of 2 quarters · filed 2026-05-07 | $405.99M derived: sum of 3 quarters · filed 2026-05-07 | $453.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $205.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $251.82M derived: sum of 2 quarters · filed 2026-03-12 | $299.25M derived: sum of 3 quarters · filed 2026-08-06 | $358.15M 10-K · filed 2026-03-12 |
| 2025-09-30 | $46.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $93.82M derived: sum of 2 quarters · filed 2026-08-06 | $152.72M 10-Q · filed 2025-11-06 | $240.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $47.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $106.32M 10-Q · filed 2026-08-06 | $193.83M derived: sum of 3 quarters · filed 2026-08-06 | $321.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $58.89M 10-Q · filed 2026-05-07 | $146.40M derived: sum of 2 quarters · filed 2026-05-07 | $274.13M derived: sum of 3 quarters · filed 2026-05-07 | $289.82M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $87.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $215.23M derived: sum of 2 quarters · filed 2026-03-12 | $230.92M derived: sum of 3 quarters · filed 2026-03-12 | $239.47M 10-K · filed 2026-03-12 |
| 2024-09-30 | $127.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $143.42M derived: sum of 2 quarters · filed 2025-11-06 | $151.97M 10-Q · filed 2025-11-06 | $185.87M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $15.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $24.24M 10-Q · filed 2025-08-07 | $58.14M derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $8.55M 10-Q · filed 2025-05-12 | $42.45M derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $33.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $63.80M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $29.90M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |